Pacific Biosciences Of California (PACB) Gross Margin (2010 - 2026)

Pacific Biosciences Of California's Gross Margin history runs 17 years deep, the most recent figure standing at 34.54% for Q1 2026.

• On a quarterly basis, Gross Margin rose 3823.0% year-over-year to 34.54% in Q1 2026; TTM through Mar 2026 was 37.49%, a 2132.0% increase from a year earlier, with the FY2025 full-year figure at 28.61%, up 440.0% from the prior year.
• Gross Margin slipped to 34.54% in Q1 2026 per PACB's latest filing, from 37.11% in the prior quarter.
• Across five years, Gross Margin topped out at 45.66% in Q2 2022 and bottomed at 3.69% in Q1 2025.
• The 5-year median for Gross Margin is 32.15% (2023), against an average of 29.28%.
• Across the five-year window, Gross Margin plunged 3276 bps in 2025 and surged 3823 bps in 2026, its largest moves.
• Year by year, Gross Margin stood at 18.79% in 2022, then retreated by 13 bps to 16.4% in 2023, then jumped by 56 bps to 25.64% in 2024, then soared by 45 bps to 37.11% in 2025, then declined by 7 bps to 34.54% in 2026.
• Per Business Quant, the three latest PACB Gross Margin figures stand at 34.54% (Q1 2026), 37.11% (Q4 2025), and 41.36% (Q3 2025).